Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects

Biochemical Pharmacology

Volumn 75, Issue 6, 2008, Pages 1272-1281

  Reuveni, Debby ^a   Halperin, Drora ^a   Shalit, Itamar ^b   Priel, Esther ^c   Fabian, Ina ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Angiogenic factors; Apoptosis; Ciprofloxacin; Cytotoxicity; Moxifloxacin; Topoisomerase I activity

Indexed keywords

CAMPTOTHECIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; INTERLEUKIN 8; LIPOCORTIN 5; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HT29; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EUKARYOTIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZA COMPOUNDS; CAMPTOTHECIN; CELL LINE, TUMOR; CIPROFLOXACIN; DNA; DNA TOPOISOMERASES, TYPE I; HUMANS; INTERLEUKIN-8; QUINOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39949084881     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.11.014     Document Type: Article

References (35)

1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6 (2006) 789-802
2. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 35 (1999) 371-379
3. Ajani J.A., Baker J., Pisters P.W., Ho L., Mansfield P.F., Feig B.W., et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophagus junction carcinoma. Cancer 94 (2001) 641-646
4. Kishida O., Miyazaki Y., Murayama Y., Ogasa M., Miyazaki T., Yamamoto T., et al. Gefitinib ("Iressa" ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 55 (2005) 393-403
5. Beretta E., Di Bartolomeo M., Buzzoni R., Ferrario E., Mariani L., Gevorgyan A., et al. Irinotecan, fluorouracil and folinic acid (folfiri) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. Tumori 92 (2006) 379-383
6. Shimada S., Yagy Y., Kuramoto m, Aoki N., and Ogawa M. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil. Oncol Rep 10 (2003) 687-691
7. Anderson V.A., and Osheroff N. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Des Pharmacol 7 (2001) 339-355
8. Bromberg K.D., Burgin A.B., and Osheroff N. Quinolone action against human topoisomerase II alpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Biochemistry 42 (2003) 3393-3398
9. Robinson M.J., Martin B.A., Gootz T.D., McGuirk P.R., Moynihan M., Sutcliffe J.A., et al. Effects of quinolone derivatives on eukaryotic topoisomerase-II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem 266 (1991) 4585-4592
10. Elsea S.H., Osheroff N., and Nitiss J.L. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J Biol Chem 267 (1992) 3150-3153
11. Miller K.G., Liu L.F., and Englund P.T. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem 256 (1981) 9334-9339
12. Hussy P., Maass G., Tümmler B., Grosse F., and Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, opoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother 29 (1986) 1073-1078
13. Shalit I., Nasrallah N., Bar-On S., and Rabau M. In vitro effect of ciprofloxacin and ofloxacin on murine and human colon carcinoma cell lines. Drugs 2 Suppl. 49 (1995) 296-297
14. Herold C., Ocker M., Ganslmayer M., Gerauer H., Hahn E.G., and Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 86 (2002) 443-448
15. Aranha O., Grignon R., Fernandes N., McDonnell T.J., Wood Jr. D.P., and Sarkar F.H. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 22 (2003) 787-794
16. Fabian I., Haite D., Levitov A., Halperin D., and Shalit I. Moxifloxacin enhances the antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer 95 (2006) 1038-1046
17. Bendetz-Nezer S., Gazit A., and Priel E. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives. Mol Pharmacol 66 (2004) 627-634
18. 2 induced ERK-1 and -2 and HIF-1α induction pathway. Carcinogenesis 25 (2004) 2303-2310
19. Plaschkes I., Silverman W.F., and Priel E. DNA topoisomerase I in mouse central nervous system: age and sex dependence. J Comp Neurol 493 (2005) 357-369
20. Har-Vardi I., Mali R., Breietman M., Sonin Y., Albotiano S., Levitas E., et al. DNA topoisomerase I and II in human mature sperm cells: characterization and unique properties. Hum Rep 22 (2007) 2183-2189
21. Bailly C., Colson P., and Houssier C. The orientation of norfloxacin bound to double-s stranded DNA. Biochem Biophys Res Commun 243 (1998) 844-848
22. Shimada S., Yagi Y., Shimori K., Kuramoto M., Aoki N., and Ogawa M. Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil. Oncol Rep 9 (2002) 783-787
23. Shimada S., Hayashi N., Marutsuka T., Baba Y., Yokoyama S., Iyama K.I., et al. Inotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases. Surg Today 32 (2002) 1075-1080
24. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000) 905-914
25. Streit M., Velasco P., Brown L.F., Shobke M., Richard L., Riccardi L., et al. Over expression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155 (1999) 441-452
26. Vanhoefer U., Harstrick A., Kohne C.H., Achterrath W., Rustum Y.M., Seeber S., et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17 (1999) 907-913
27. Somekh E., Douer D., Shaked N., and Rubinstein E. In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J Pharmacol Exp Ther 248 (1989) 415-418
28. Miclau T., Edin M.L., Lester G.E., Lindsey R.W., and Dahners L.E. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 16 (1998) 509-512
29. Ebisuno S., Inagaki T., Kohjimoto Y., and Ohkawa T. The cytotoxic effects of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 80 (1997) 2263-2267
30. Yamakuchi M., Nakata M., Kawahara K., Kitajima I., and Maruyama I. New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines. Cancer Lett 119 (1997) 213-219
31. Aranha O., Wood D.P., and Sarkar F.H. Ciprofloxacin mediated cell growth inhibition, S/G(2)-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res 6 (2000) 891-900
32. Weiss T., Shalit I., Blau H., Werber S., Halperin D., Levitov A., et al. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NFκB and MAPK activation and synthesis of proinflammatory cytokines. Anti Microb Agents Chem 48 (2004) 1974-1982
33. Shalit I., Halperin D., Haite D., Levitov A., Romano J., Osherov N., et al. Anti-inflammatory effects of moxifloxacin on IL-8, IL-1β, and TNF-α secretion and NFκB and MAP-kinase activation in human monocytes stimulated with aspergillus fumigatus. J Antimic Chemother 57 (2006) 230-235
34. Werber S., Shalit I., Fabian I., Steuer G., Weiss T., and Blau H. Moxifloxacin inhibits cytokine-induced nitric oxide production and down-regulates expression of Inos, NFκB and MAP kinases in human respiratory epithelial cells. J Antimic Chemother 55 (2005) 293-300
35. Shalit I., Horev L., Fabian I., Blau H., Kariv N., Shechtman I., et al. Immunomodulatory and protective effects of moxifloxacin against Candida albicans induced bronchopneumonia in cyclophosphamide injected mice. Antimicrob Agents Chemother 46 (2002) 2442-2449